
Commentary|Videos|December 9, 2024
Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma
Author(s)Robert M. Rifkin, MD, FACP
Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.
Advertisement
Robert M. Rifkin, MD, FACP, medical oncologist, hematologist, Rocky Mountain Cancer Centers, discusses overall survival analysis and efficacy outcomes from the phase 3 Dreamm-7 trial (NCT04246047) in patients with relapsed/refractory multiple myeloma. Rifkin and colleagues shared this data in a presentation at the 2024 ASH Annual Meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5



































